CSIMarket
 
Homology Medicines Inc  (FIXX)
Other Ticker:  
 
 
Price: $0.9157 $-0.01 -1.251%
Day's High: $0.94 Week Perf: 0.64 %
Day's Low: $ 0.92 30 Day Perf: 29.89 %
Volume (M): 150 52 Wk High: $ 1.48
Volume (M$): $ 138 52 Wk Avg: $0.93
Open: $0.92 52 Wk Low: $0.46



 Market Capitalization (Millions $) 53
 Shares Outstanding (Millions) 58
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Homology Medicines Inc
Homology Medicines Inc is a genetic medicines company that develops and commercializes treatment options for rare genetic diseases. The company utilizes its proprietary platform called Homology Technology Platform, which enables the precise and efficient delivery of genetic medicines to target and correct underlying genetic mutations. Homology Medicines aims to address a wide range of genetic diseases by focusing on the correction of DNA within the patient's own cells. Their goal is to provide personalized medicines that can potentially cure genetic diseases.


   Company Address: One Patriots Park Bedford 1730 MA
   Company Phone Number: 301-7277   Stock Exchange / Ticker: NASDAQ FIXX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Dividend

Homology Medicines Empowers Common Stockholders with Contingent Value Rights

Published Mon, Mar 18 2024 8:30 PM UTC

Homology Medicines Declares Distribution to Common Stockholders
Homology Medicines, Inc. (Nasdaq: FIXX) has declared a distribution to its common stockholders of record as of March 21, 2024, granting them the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held. The payment date for this distribution is expected to be...

Homology Medicines Inc

Major Pharmaceutical Preparations Companies Show Steady Revenue Growth in Third Quarter of 2023

Homology Medicines Inc, a genetic medicines company, recently released their earnings report for the third quarter of 2023. Despite an improvement in earnings per share (EPS) and a decrease in net loss, the company's revenue remained unchanged.
Comparing the third quarter of 2023 to the same period the year before, Homology Medicines Inc saw a decrease in their loss per share. In the third quarter of 2023, the company reported a loss of $-0.57 per share, compared to a loss of $-0.59 per share in the previous year. Furthermore, their EPS showed improvement, going from $-0.61 per share in the prior reporting season to $-0.57 per share.

Homology Medicines Inc

Critical Quarter for FIXX as Homology Medicines Inc Reports Drastic Revenue Decline in Jun 30, 2023

Despite the disastrous Jun 30, 2023 report released by Homology Medicines Inc, a major pharmaceutical preparations company, there is reason to remain bullish about the company's future prospects.
The report states that Homology Medicines Inc experienced a significant decline in revenue, with a falloff of -55.86% to $0.35 million. Additionally, the net loss per share has widened to $-0.61 from the same reporting period a year ago, compared to the previous quarter where it stood at $-0.50 per share. Furthermore, revenue tumbled proportionally by -55.86% from $0.80 million.

Homology Medicines Inc

Shortfall in Revenues but Promising Progress for Homology Medicines Inc in the Field of Gene Therapy

Homology Medicines Inc: A Biotech Company Focused on Gene Therapy
Homology Medicines Inc is a biotech company that is focused on developing gene therapies for rare diseases. The company was founded in 2015 and is based in Bedford, Massachusetts. Homology Medicines is a preclinical stage company with a pipeline of novel gene therapy programs, focused on the treatment of rare genetically driven diseases. The company is committed to developing next-generation gene therapies that are more efficient, effective, and affordable than current treatments.
Homology Medicines' Gene Therapy Platform
Homology Medicines uses a proprietary gene therapy platform that is based on a naturally occurring process called homologous recombination. Homologous recombination is a process in which cells repair damaged DNA by using a healthy copy of the same DNA sequence as a template. The company has developed a technology that allows them to harness this process to create new genes that can be targeted to specific areas of the genome.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com